Gadopentetate dimeglumine
Updates to Article Attributes
Gadopentetate dimeglumine (also known as MagnevistTM
linear, ionic molecule
100% renally excreted
T1 relaxivity @ 1.5 T: 3.9-4.3
concentration: 0.5 mmol/mL
recommended dosage: 0.1 mmol/kg
Indications
As an extracellular contrast agent, gadopentetate dimeglumine can be usefulused in a wide range of MRI applications, including (but not limited to): hepatic imaging, pelvic imaging, cardiac imaging, brain and spine imaging, and musculoskeletal imaging.
Contraindications
There is an association between the use of gadolinium-based contrast agents (GBCAs) in patients with kidney dysfunction and nephrogenic systemic fibrosis (NSF), a rare, but serious, condition. As a result, the use of three GBCAs; gadopentetate dimeglumine (Magnevist®), gadodiamide (Omniscan®), and gadoversetamide (OptiMARK®) are contraindicated in patients with AKIacute kidney injury or with chronic, severe kidney disease 2.
-<p><strong>Gadopentetate dimeglumine</strong> (also known as <strong>Magnevist<sup>TM</sup></strong>) is an extracellular intravenous contrast agent used in magnetic resonance imaging.</p><ul>-<li>linear, ionic molecule </li>-<li>100% renally excreted</li>-<li>T1 relaxivity @ 1.5 T: 3.9-4.3</li>-<li>concentration: 0.5 mmol/mL</li>-<li>recommended dosage: 0.1 mmol/kg</li>-</ul><h5>Indications</h5><p>As an extracellular contrast agent, gadopentetate dimeglumine can be useful in a wide range of MRI applications, including (but not limited to): hepatic imaging, pelvic imaging, cardiac imaging, brain and spine imaging, and musculoskeletal imaging.</p><h5>Contraindications</h5><p>There is an association between the use of <a href="/articles/gadolinium-contrast-agents">gadolinium-based contrast agents (GBCAs)</a> in patients with kidney dysfunction and <a href="/articles/nephrogenic-systemic-fibrosis">nephrogenic systemic fibrosis (NSF)</a>, a rare, but serious, condition. As a result, the use of three GBCAs; gadopentetate dimeglumine (Magnevist®), gadodiamide (Omniscan®), and gadoversetamide (OptiMARK®) are contraindicated in patients with AKI or with <a title="Chronic kidney disease" href="/articles/chronic-kidney-disease">chronic, severe kidney disease </a><sup>2</sup>.</p>- +<p><strong>Gadopentetate dimeglumine</strong> (also known as <strong>Magnevist</strong>) is an extracellular intravenous contrast agent used in magnetic resonance imaging.</p><ul>
- +<li><p>linear, ionic molecule </p></li>
- +<li><p>100% renally excreted</p></li>
- +<li><p>T1 relaxivity @ 1.5 T: 3.9-4.3</p></li>
- +<li><p>concentration: 0.5 mmol/mL</p></li>
- +<li><p>recommended dosage: 0.1 mmol/kg</p></li>
- +</ul><h5>Indications</h5><p>As an extracellular contrast agent, gadopentetate dimeglumine can be used in a wide range of MRI applications, including (but not limited to): hepatic imaging, pelvic imaging, cardiac imaging, brain and spine imaging, and musculoskeletal imaging.</p><h5>Contraindications</h5><p>There is an association between the use of <a href="/articles/gadolinium-contrast-agents">gadolinium-based contrast agents (GBCAs)</a> in patients with kidney dysfunction and <a href="/articles/nephrogenic-systemic-fibrosis">nephrogenic systemic fibrosis (NSF)</a>, a rare, but serious, condition. As a result, the use of three GBCAs; gadopentetate dimeglumine (Magnevist), gadodiamide (Omniscan), and gadoversetamide (OptiMARK) are contraindicated in patients with acute kidney injury or with <a href="/articles/chronic-kidney-disease" title="Chronic kidney disease">chronic, severe kidney disease </a><sup>2</sup>.</p>
Unable to process the form. Check for errors and try again.